DAFTAR PUSTAKA

1. Lubis HR. Penyakit ginjal diabetik. In Setiati S, Alwi I, Sudoyo A, Simadibrata M, Setiyohadi B, Syam A, editors. Buku Ajar Ilmu Penyakit Dalam. Jilid I edisi VI. Jakarta: Interna Publishing. 2014; 2102–05.
2. World Health Organization. Global report on diabetes. WHO library cataloguing. 2016; 1–84.
3. Suharjono. Gagal Ginjal Kronik. Dalam: Buku Ajar Ilmu Penyakit Dalam. Jilid II edisi III. Jakarta: Pusat Penerbit FKUI. 2008.
4. Wu AYT, Kong NCT, De Leon FA, Pan CY, Tai TY, Yoo SJ. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients : the MAP study. Diabetologia. 2005;48:17–26.
5. Indonesian renal registry. 8th Report Of Indonesian Renal Registry. IRR. 2015;1–45.
6. Gheith O, Farouk N, Nampoory N, Halim AM, Al-Otaibi T. Diabetic kidney disease : world wide difference of prevalence and risk factors. JNephropharmacol. 2016;5(1):49–56.
7. Eppens MC, Craig ME, Cusumano J, Hing SC, Howard N J, Silink M et al. Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care. 2006;29:1300–6.
8. Odegaard JI, Chawla A. Connecting type 1 and type 2 diabetes through innate immunity. Cold Spring Harb Perspect Med. 2012;2(3):1–18.
9. Chiarelli F, Gaspari S, Marcovecchio ML. Role of growth factors in diabetic kidney disease. Horm Metab Res. 2010;41(8):585–93.
10. Macisaac RJ, Ekinci EI, Jerums G. Markers of and risk factors for the development and progression of diabetic kidney disease. Am J Kidney Dis. 2014;63:S39–S62.
11. Tervaert TW, Mooyaart AL, Amann K, Cohen AH, Cook HT, Joh K et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010 Apr. 21 (4):556–63.
12. Loeffler I, Wolf G. Transforming growth factor-beta and the progression of renal disease. Nephrol Dial Transplant 2014;29(1):137–145.
13. Ali Z. Albuminuria sebagai penanda progresivitas penyakit ginjal diabetik. Dalam : Naskah Lengkap The 11th Jakarta Nephrology and hypertension Course and Symposium on Hypertension. Pernefri. 2011;53–63.
14. Miner JH. The glomerular basement membrane. Experimental Cell Research. 2012;318:973–8.
15. Leeuwis JW, Nguyen TQ, Dendooven A, Kok RJ, Goldschmeding R. Targeting podocyte-associated diseases. Advanced drug delivery reviews. 2010;62:1325–36.
16. Loeffler I, Wolf G. Epithelial-to-mesenchymal transition in diabetic nephropathy :fact or fiction?. Cells. 2015;4:631–52.
17. Reidy K, Susztak K. Epithelial mesenchymal transition and podocyte loss in diabetic kidney disease. Am J Kidney Dis. 2009;54(4):590–93.
18. He Z. Diagnosis and treatment of diabetic nephropathy in type 1 and type 2 diabetes patients. J Mol Biomark Diagn. 2016;7(5):1–4.

19. Singh J. Evaluation of diabetic nephropathy: clinical recommendations. Medicine update. 2014;45:255–260.

20. Vujicic B, Turk T, Orlic CZ, Dordevic G, Racki S. Diabetic nephropathy. InTech. 2012;4:71–96.

21. Maclsaac RJ, Tsalamandris C, Panagiotopoulus S, Smith TJ, McNeill KJ, Jerums G. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care. 2004;27:195–200.

22. Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int. 2002;61(6):2165–75.

23. Tramonti G, Kanwar YS. Review and discussion of tubular biomarkers in the diagnosis and management of diabetic nephropathy. Endocrine. 2013;43:494–503.

24. Kamijo-Ikemori A, Sugaya T, Kimura K. Novel urinary biomarkers in early diabetic kidney disease. Curr Diabetes Rep. 2014;14:513.

25. Gluhovschi C, Gluhovschi G, Petrica L, Timar R, Velciov S, Ionita I. Urinary biomarkers in the assesment of early diabetic nephropathy. Journal of diabetes research. 2016;1–13.

26. Uwaezuoke SN. The role of novel biomarkers in predicting diabetic nephropathy: a review. International journal of nephrology and renovascular disease. 2017;10:221–231.

27. Lacquaniti A, Donato V, Pintaudi B, Di Vieste G, Chirico V, Buemi A et al. "Normoalbuminuric" diabetic nephropathy: tubular damage and NGAL.Acta Diabetol. 2013; 50(6):935–42.

28. Fiseha T. Urinary biomarkers for early diabetic nephropathy in type 2 diabetic patients. Biomark Res. 2015;3(1):16.

29. Currie G, McKay G, Delles C. Biomarkers in diabetic nephropathy: present and future. World J Diabetes. 2014;5(6):763–776.

30. Navarro JF, Moya C. Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy. ScientificWorldJournal. 2006:9(6):908–17.

31. Nigro P, Pompilio G, Capogrossi MC. Cyclophilin A: A key player for human disease. Citation: Cell Death and Disease. 2013;4:1–9.

32. Satoh K, Shimokawa H, Berk BC. Cyclophilin A: promising new target in cardiovascular therapy. Circ J. 2010;74:2249–2256.

33. Ramachandran S, Venugopal A, Sathisha K. Proteomic profiling of high glucose primed monocytes identifies cyclophilin A as a potential secretory marker of inflammation in type 2 diabetes. Proteomics. 2012;12:2808–2821.

34. Tsai SF, Su CW, Wu MJ, Chen CH, Fu CP, Liu CS et al. Urinary cyclophilin A as a new marker for diabetic nephropathy. Medicine. 2015:94(42):1–10.

35. Mishra R, Emancipator SN, Kern T. High glucose evokes an intrinsic proapoptotic signaling pathway in mesangial cells. Kidney Int 2005;67(1):82–93.

36. Hsieh M, Tsai MF. The role of secreted cyclophilin A in diabetic nephropathy. Tunghai University Taiwan. 2016;1–92.

37. Tsai SF, Hsieh CC, Wu MJ, Chen CH, Lin TH, Hsieh M. Novel findings of secreted cyclophilin A in diabetic nephropathy and its association with renal protection of dipeptidyl peptidase 4 inhibitor. Clin Chim Acta. 2016 Dec 1;463:181–192.

38. Ye H, Bai X, Gao H. Urinary podocalyxin positive element occurs in the early stage of diabetic nephropathy and is correlated with clinical diagnosis of diabetic nephropathy. J Diabetes complication. 2014;28(1):2913–19.

39. Panduru NM, Forsblom C, Saraheimo M. Urinary liver type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes. Diabetes care. 2013;36(7):2077–83.

40. Haneda M, Utsunomiya K, Koya D, et al. A new classification of diabetic nephropathy 2014. J Diabetes Invest. 2015;6:242–246.

41. Tseng C. Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetes mellitus in Taiwan. Kidney International. 2005;68:796–801.

42. Norma S, Azmi MT, Rotina AB. Factors that influence albuminuria among type 2 diabetes mellitus at primary healthcare clinics in negeri Sembilan. Journal of Community Health. 2010;16:21–32.

43. Bonakdaran S, Hami M, Shakeri MT. Hyperuricemia and albuminuria in patients with type 2 diabetes mellitus. Iranian Journal of Kidney Disease. 2011;5:21–4.

44. Chul-Woo Y, Jung TP, Yon SK, Yong LK, Yil-Seob L, Yoon-Sun et al. Prevalence of diabetic nephropathy in primary care type 2 diabetic patients with hypertention : data from Korean epidemiology study on hypertention III. Nephrol Dial Transplant. 2011;26:3249–55.

45. Behraadmanesh S, Horestani MK, Nasri H. Association of serum uric acid with proteinuria in type 2 diabetic patients. Medical Sciences : The Official Journal of Isfahan University of Medical s. 2013;18:44–6.

46. Balai penelitian dan pengembangan kesehatan. Riset kesehatan dasar.Kementrian kesehatan RI. 2013.

47. Gupta KK, Patel ML, Sachan R, Uniyal R. Clinical correlation beetwen ApoB/ApoA1 Ratio in type 2 diabetic nephropathy-A tertiary centre experience. International Journal of scientific. 2012;9:2250–3.

48. Hui-Mei C . Wen-Wen S, Yong-Chun G, Yi-De Z, Hong-Lang X, Zhi-Hong L. The relationship between obesity and diabetic nephropathy in China. BMC Nephrology. 2013;14:69–75.

49. Amer HMA, Sabry IM, Bekhet MM, Mohammed RNS. The role of urinary cyclophilin A as a new marker for diabetic nephropathy. The Egyptian Journal of Hospital Medicine. 2018;70(9):1431–1439.

50. Chowta NK, Pant P, Chowta MN. Microalbuminuria in diabetes mellitus: association with age, sex, weight and creatinine clearance. Indian J. Nephrol. 2009;19(2):53–6.

51. Pradip R, Jayanta D. Changes in microalbuminuria in relation to glycosylated haemoglobin and duration in type 2 diabetes mellitus. Indian medical gazette. 2012:394–9.

52. Noha A, Gamal A. Evaluation of oxidative stress markers and vascular risk factor in patient with diabetic nephropathy. Cell Biochemistry and Function. 2012;30(4):328–34.

53. Masahiko T. Trigliserida, but not total cholesterol or low density lipoprotein cholesterol level predict development of proteinuria. Kidney International. 2008;62:1743–9.

54. Yassamine B, Latrech H, Abouqal R. Does body mass index influence the decline of glomerular filtration rate in diabetic type 2 patients with diabetic nephropathy in developing country?. Renal Failure. 2014;36:838–46.

55. Van Buren PN, Tato R. Hypertention in diabetic nephropathy: Epidemiology, mechanism and management. Adv Chronic Kidney Dis. 2011;18(1):28–41.

56. Syrjanen J. Hypertrigliseridemia and hyperuricemia risk factor for progression of IgA nephropathy. Nephrol Dial Transplant. 2000;15:34–42.

57. Nakhjavani M, Esteghamati A, Abbasi M. Albuminuria and its correlated in an Iranian type 2 diabetic population. Lipid in health and disease. 2008;7:28.

58. Maharjan BR, Bandary S, Sunuwar L, Shresta A. Association of hypertension with microalbuminuria and lipid profile in the local population of Patan. Nepal Med Coll J. 2012;14(2):157–62.

59. Soelistijo SA, Novida H, Rudijanto A, Soewondo P, Suastika K, Manaf A et al. Konsensus pengelolaan dan pencegahan diabetes mellitus tipe 2 di Indonesia. PB Perkeni. 2015;1–82.

60. Bitzur R, Cohen H, Kamari Y, Shaish H, Harat D. Triglycrides and HDL cholesterol: stars or second lead in diabetes. Daibetes care. 2009;32(2):373–77.

61. Woerle HJ, Neumann C, Zschau S, et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes: importance of postprandial glycemia to achieve target HbA1c levels. *Diabetes Res Clin Pract*. 2007;77:280–285.

62. Vinod PB. Patophysiology of diabetic nephropathy. Clinical Queries : Nephrology. 2012;102:121–6.

63. Kundu D, Roy A, Mandal T, Bandyopadhyay U, Ghosh E, Ray D. Relation of microalbuminuria to glycosylated hemoglobin and duration of type 2 diabetes. Cross Citations Ref. 2013;16(2):216–220.

64. Dizin E, Hasler U, Stellor NK, Fila M, Roth I, Ernandez T et al. Albuminuria induces a proinflammatory and profibrotic response in cortical collecting ducts via the 24p3 receptor. Am J Physiol Renal Physiol. 2013;305(8):1100–8.

65. Aziz KM. Correlation of urine biomarkers: microalbuminuria and spot urine protein among diabetic patients. Metab Immune Drug Discov. 2015;9(2):121–33.

66. Astor BC, Matsushita K, Gansevoort RT. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011;79:1331–40.

67. Gansevoort RT, Matsushita K, Van der Velde M. Chronic kidney disease prognosis consortium. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 2011;80:93–104.

68. Zhang L, Li Z, Zhang B, He H, Bai Y. PPIA is novel adipogenic factor implicated in obesity. Obesity. 2015;23:2093–2100.

69. Chang SC, Su SL, Chang CC, Lee KW, Kuo CL, Huang CS et al. Cyclophilin A: a novel biomarker for untreated essential hypertension. 2013;18(8):716–20.

70. Heinzmann D, Bangert A, Muller AM, Emschermann F, Schoenberger T, Chatterjee M. The novel extracellular cyclophillin A (Cyp A) inhibitor MM284 reduces myocardial inflammation and remodeling in a mouse model of troponin I induced myocarditis. Plos one. 2015;10(4):1-11.